Heated tobacco product

NCLA Amicus Brief Tells D.C. Circuit It Must Avoid Remanding Regulations Without Vacating Them

Retrieved on: 
월요일, 4월 22, 2024

NCLA released the following statements:

Key Points: 
  • NCLA released the following statements:
    “The ‘remand without vacatur’ doctrine licenses administrative agencies to act contrary to law with the court’s (unintentional) blessing.
  • Circuit will recognize the terrible error at the heart of this doctrine and will act accordingly.”
    “A regulation is either lawful or unlawful.
  • There is no provision for sending the rule back to the agency to simply add a missing ingredient and re-bake it.
  • Nor does the half-baked ‘remand without vacatur’ doctrine properly incentivize agencies to follow the law in the first instance.”

Albertsons Companies Wins ‘People’s Voice’ Webby Award for Best Shopping and Retail App

Retrieved on: 
화요일, 4월 30, 2024

Albertsons Companies announced today that the retailer was voted the ‘People’s Voice’ winner for best shopping and retail app in the 28th annual Webby Awards.

Key Points: 
  • Albertsons Companies announced today that the retailer was voted the ‘People’s Voice’ winner for best shopping and retail app in the 28th annual Webby Awards.
  • Over the last year, Albertsons Cos. has been updating and redesigning its mobile app to create a fast and easy digital shopping experience.
  • View the full release here: https://www.businesswire.com/news/home/20240430367531/en/
    Albertsons Companies was voted the ‘People’s Voice’ winner for best shopping and retail app in the 28th annual Webby Awards.
  • Albertsons Cos. will be honored at the 28th Annual Webby Awards commemoration in New York City on May 13.

FDA Approves New Treatment for Uncomplicated Urinary Tract Infections

Retrieved on: 
수요일, 4월 24, 2024

SILVER SPRING, Md., April 24, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.

Key Points: 
  • SILVER SPRING, Md., April 24, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.
  • "The FDA is committed to fostering new antibiotic availability when they prove to be safe and effective, and Pivya will provide an additional treatment option for uncomplicated UTIs."
  • Uncomplicated UTIs are bacterial infections of the bladder in females with no structural abnormalities of their urinary tract.
  • Approximately one-half of all women experience at least one UTI in their lifetime.

InventHelp Inventor Develops New Retractable Leash for Dogs(LGI-2988)

Retrieved on: 
월요일, 4월 15, 2024

PITTSBURGH, April 15, 2024 /PRNewswire/ -- "I wanted to create a retractable dog leash with added features to increase safety and convenience when walking a dog," said an inventor, from Massapequa Park, N.Y., "so I invented the MACGYVER LEASH.

Key Points: 
  • PITTSBURGH, April 15, 2024 /PRNewswire/ -- "I wanted to create a retractable dog leash with added features to increase safety and convenience when walking a dog," said an inventor, from Massapequa Park, N.Y., "so I invented the MACGYVER LEASH.
  • The patent-pending invention provides a new retractable leash for dogs.
  • The original design was submitted to the Long Island sales office of InventHelp.
  • 22-LGI-2988, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

FDA Roundup: April 9, 2024

Retrieved on: 
화요일, 4월 9, 2024

The system includes the use of a motion scaling function, which scales down the surgeon's movements.

Key Points: 
  • The system includes the use of a motion scaling function, which scales down the surgeon's movements.
  • Microsurgery covers procedures involving the use of microscopes and small instruments to perform small-scale surgical techniques.
  • The system is intended for use by trained physicians in the operating environments described in the device's labeling.
  • On Friday, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

If plastic manufacturing goes up 10%, plastic pollution goes up 10% – and we’re set for a huge surge in production

Retrieved on: 
목요일, 4월 25, 2024

As plastic manufacturers increase production, more and more of it will end up in our landfills, rivers and oceans.

Key Points: 
  • As plastic manufacturers increase production, more and more of it will end up in our landfills, rivers and oceans.
  • Producers often put the onus back on consumers by pointing to recycling schemes as a solution to plastic pollution.
  • The key question here is how close the is relationship between plastic production and pollution.
  • Not only that, but over half of branded plastic pollution is linked to just 56 companies worldwide.
  • Socially and economically, plastic pollution now costs us about A$3.8 trillion a year.

Plastic fantastic?

  • Today, about 36% of all the world’s plastic pollution comes from the packaging sector in the form of single-use plastics.
  • To find out how plastic production influences waste, we turned to global data from litter audits, surveys of waste in the environment.
  • Data from these audits is useful to understand changes in types and volumes of plastic waste.
  • The Coca-Cola Company products were the top source of branded plastic pollution, representing 11% of all branded litter.
  • Right now, companies get to sell their products in single-use plastics and the onus is on consumers to recycle or bin the plastic.

The problem of single-use plastics

  • Even when collected, single-use plastics are a difficult waste stream to manage as they have little or no recycling value.
  • Sometimes these plastics are burned as fuel for cement kilns or used in waste-to-energy facilities.

To stop plastic waste, stop making more plastic


If recycling and landfilling can only go so far, the missing piece of the puzzle has to be capping plastic production. What would that look like? It would involve requiring manufacturers to steadily reduce the amount of plastic used in their products over time and adopt safe, sustainable plastic alternatives as they become available. Countries could:
set measurable targets to phase out non-essential, hazardous and unsustainable single-use products, such as take-away containers, plastic cutlery and single-use plastic bags
work to design safe and sustainable products to cut global demand for new plastic while increasing reuse, refilling, repairing, and recycling
invest in non-plastic alternatives and substitutes with better social, economic and environmental profiles, such as old-fashioned reusables.

  • One thing is certain – current trends mean ever more plastic, and more plastic means more plastic pollution.
  • Read more:
    The climate impact of plastic pollution is negligible – the production of new plastics is the real problem
  • None of the funding received in any way relates to the work discussed or highlighted in this article.
  • Win Cowger receives funding from Possibility Lab, Break Free From Plastic, National Renewable Energy Laboratory, and McPike Zima Charitable Foundation.

Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board

Retrieved on: 
화요일, 4월 9, 2024

“We believe our proprietary drug-device combination platform has the potential to be a first-in-class and best-in-class treatment for smoking cessation.

Key Points: 
  • “We believe our proprietary drug-device combination platform has the potential to be a first-in-class and best-in-class treatment for smoking cessation.
  • Last fall, QN-01 demonstrated a superior pharmacokinetic profile compared to existing nicotine replacement therapies in our first-in-human Phase 1 clinical trial.
  • We plan to submit our IND and CTA to the regulatory bodies and look forward to commencing our Phase 1/2 clinical study this year.
  • He also served a three-year term on the Board of the Society for Research on Nicotine and Tobacco.

Philip Morris International Demonstrates Clear Progress Toward Its Purpose as It Releases 2023 Integrated Report

Retrieved on: 
목요일, 3월 28, 2024

Please visit pmi.com/sustainability to learn more, and read the full 2023 Integrated Report , case studies and market stories , and the Sustainability KPI Protocol 2023 .

Key Points: 
  • Please visit pmi.com/sustainability to learn more, and read the full 2023 Integrated Report , case studies and market stories , and the Sustainability KPI Protocol 2023 .
  • 2 For definition of net revenues related to smoke-free products, see Glossary available on pages 208-212 of PMI Integrated Report 2023.
  • 3 For definition of available for sale, see Glossary available on pages 208-212 of PMI Integrated Report 2023.
  • For definition of low- and middle-income markets, see Glossary available on pages 208-212 of PMI Integrated Report 2023.

Altria to Significantly Enhance Cash Returns to Shareholders Through Expanded Share Repurchase Program in Connection with Pricing of Offering of Anheuser-Busch InBev Stock; Raises 2024 Full-Year Earnings Guidance

Retrieved on: 
목요일, 3월 14, 2024

In connection with the pricing of the offering, we announce a $2.4 billion increase to our existing $1 billion share repurchase program.

Key Points: 
  • In connection with the pricing of the offering, we announce a $2.4 billion increase to our existing $1 billion share repurchase program.
  • Our Board of Directors (Board) has authorized the expanded program, which we expect to complete by December 31, 2024.
  • Share repurchases depend on marketplace conditions and other factors, and the program remains subject to the discretion of our Board.
  • As part of the expanded share repurchase program, we expect to enter into an estimated $2.4 billion accelerated share repurchase (ASR) program.

FDA Approves New Antibiotic for Three Different Uses

Retrieved on: 
수요일, 4월 3, 2024

"The FDA will continue our important work in this area as part of our efforts to protect the public health."

Key Points: 
  • "The FDA will continue our important work in this area as part of our efforts to protect the public health."
  • Zevtera's efficacy in treating SAB was evaluated in a randomized, controlled, double-blind, multinational, multicenter trial .
  • In the trial, researchers randomly assigned 390 subjects to receive Zevtera (192 subjects) or daptomycin plus optional aztreonam [the comparator] (198 subjects).
  • A total of 69.8% of subjects who received Zevtera achieved overall success compared to 68.7% of subjects who received the comparator.